EQUILLIUM, INC. Increase (Decrease) in Deferred Revenue
EQUILLIUM, INC. (EQ) reported Increase (Decrease) in Deferred Revenue of -$15.73 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-03-25
- EQUILLIUM, INC. increase (decrease) in deferred revenue for the quarter ending 2024-12-31 was -$2.07M.
- EQUILLIUM, INC. increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was -$6.36M.
- EQUILLIUM, INC. increase (decrease) in deferred revenue for the quarter ending 2024-06-30 was -$4.93M.
- EQUILLIUM, INC. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was -$2.37M.
- EQUILLIUM, INC. increase (decrease) in deferred revenue for fiscal 2024 was -$15.73M.
- EQUILLIUM, INC. increase (decrease) in deferred revenue for fiscal 2023 was -$9.35M, a 137.28% decline from fiscal 2022.
- EQUILLIUM, INC. increase (decrease) in deferred revenue for fiscal 2022 was $25.08M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$8.43M derived: sum of 2 quarters · filed 2026-03-25 | -$13.36M derived: sum of 3 quarters · filed 2026-03-25 | -$15.73M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$6.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$11.29M derived: sum of 2 quarters · filed 2025-11-13 | -$13.66M 10-Q · filed 2025-11-13 | -$16.18M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$4.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$7.30M 10-Q · filed 2025-08-14 | -$9.82M derived: sum of 3 quarters · filed 2025-08-14 | -$11.77M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$2.37M 10-Q · filed 2025-05-14 | -$4.89M derived: sum of 2 quarters · filed 2025-05-14 | -$6.83M derived: sum of 3 quarters · filed 2025-05-14 | -$9.35M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$4.47M derived: sum of 2 quarters · filed 2025-03-27 | -$6.98M derived: sum of 3 quarters · filed 2025-03-27 | -$9.35M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$4.46M derived: sum of 2 quarters · filed 2024-11-13 | -$6.83M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$4.88M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$2.37M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $25.08M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |